Previous 10 | Next 10 |
Rigel Pharmaceuticals (RIGL) recently reported their Q1 earnings and hosted a conference call to update investors on the TAVALISSE launch, as well as pipeline progress and the company's financials. Rigel reported $8.1M in net product sales from TAVALISSE, which was a 10% increase quarter...
BARCELONA, Spain , April 30, 2019 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of technologies and services for hospitals, clinics and compounding centers, announced today that its PharmacyKeeper...
HINESVILLE, Ga. , April 29, 2019 /PRNewswire/ -- Grifols is pleased to announce the opening of a new Biotest plasma donor center located at 108 West Hendry Street, Hinesville , Georgia. The 11,000 square foot state-of-the-art facility officially opened its doors for bu...
RALEIGH, N.C. , April 18, 2019 /PRNewswire/ -- Grifols, one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that its U.S. network of over 220 donor centers collaborated with local food banks and pantries to collect more th...
BARCELONA, Spain , April 15, 2019 /PRNewswire/ -- Grifols, one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that its long-term global initiative to providing treatment to people with hemophilia in developing region...
BARCELONA, Spain , April 5, 2019 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS) announced that it has filed its 2018 Annual Report on Form 20-F with the United States Securities and Exchange Commission ("SEC") on April 5, 2019 . Grifols' Annual R...
RUSSELLVILLE, Ark. , March 23, 2019 /PRNewswire/ -- Grifols is pleased to announce the opening of a new Biotest plasma donor center located at 1105 W Main Street, Russellville , Arkansas. The 15,000 square foot state-of-the-art facility officially opened its doors for business on M...
Deals and Financings Grifols (MCE: GRF, [[GRFS]]), a Barcelona maker of plasma-based medicines, acquired a 26% stake in Shanghai RAAS (SHZ: 002252), one of China's largest blood plasma companies, for $1.9 billion in a non-cash deal. Grifols will exchange a 45% ownership in its US subsidi...
BARCELONA, Spain , Feb. 21, 2019 /PRNewswire/ -- Grifols has earned the honor of 2019 Category Leader in IV Workflow Management in the 2019 Best in KLAS: Software & Services report for its PharmacyKeeper Verification product. This marks the third consecutive y...
BARCELONA, Spain , Feb. 7, 2019 /PRNewswire/ -- Grifols, a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, announced today that the U.S. Food and Drug Administration (FDA) approved the Procleix Babesia assay, a qual...
News, Short Squeeze, Breakout and More Instantly...
2024-06-12 02:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Grifols 2023 Annual Report on Form 20-F filed with the SEC PR Newswire BARCELONA, Spain , April 19, 2024 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived me...
2024-03-23 01:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...